PPD

Thermo Fisher completes $17.4B acquisition of PPD

Thermo Fisher Scientific (NYSE:TMO) announced today that it completed its previously announced $17.4 billion acquisition of PPD.

Waltham, Massachusetts-based Thermo Fisher announced in April that it would acquire the company that provides clinical research services to the biopharma and biotech industry. PPD ceased trading on the Nasdaq prior to opening today and will become part of Thermo Fisher’s laboratory products and services segment.

The boards of directors for both companies approved the definitive agreement back in April, which confirmed that Thermo Fisher would buy PPD for $47.50 per share, totaling $17.4 billion, plus the assumption of approximately $3.5 billion of net debt, according to a news release. That represents a premium of approximately 24% to the unaffected closing price of PPD’s common stock on Tuesday, April 13, 2021.

Wilmington, N.C.-based PPD offers clinical research and laboratory services to enable customers to accelerate i…

Medtech M&A: The industry’s biggest mergers and acquisitions of 2021

[Image from Jp Valery on Unsplash]

Across 2021, medtech has seen a wide range of mergers and acquisitions covering several areas of devices, pharmaceuticals and more.

Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.

Here are the 10 biggest mergers and acquisitions in medtech in 2021:

Next>>